Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
2 FDA Grants Priority Review for Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal
3 Merck (MRK) Gets Priority Tag for Pneumococcal Vaccine BLA
4 Bla bla bla for biodiversity
5 Provention Bio Announces US FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
6 Manufacturers submit rolling BLA to FDA for CAR-T to treat advanced multiple myeloma
7 Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
8 FDA Accepts BLA for Pediatric GHD Drug
9 FDA Defers Action on BLA for Bevacizumab Biosimilar MYL-1402O
10 FDA Defers BLA Action of Bevacizumab Biosimilar Due to COVID-19 Restrictions
11 Pfizer's (PFE) BLA for Somatrogon Gets FDA's Acceptance
12 POTD: A comical corgi bloodbath and a miracle gas blast escape
13 Bla Bla Beach Club to open this week
14 Transportation Aggregators Market 2021-2028 Culminated to Grow High by profiling companies: Uber Technologies,ANI Technologies,Lyft,Gett,Shippr,Grab Holdings,Bla Bla,Fehr&Peers,BlackBuck
15 Merck : FDA Accepts For Priority Review BLA For Adult Invasive Pneumococcal Vaccine
16 Humanigen Announces the Addition of BARDA and Expansion of CRADA with the US Government to Develop Lenzilumab for COVID-19
18 Bla Bla: JBR's huge new beach club is set to open this Thursday
19 Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
20 More than 50 countries commit to protecting 30% of Earth’s land and oceans
21 FDA Grants Priority Review to Treatment for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
22 USFDA defers action on BLA for Avastin biosimilar, notifies Biocon Biologics, Mylan
23 New Orange & Purple Book laws increase transparency of patent information for drugs, biologics
24 Balochistan: BLA claimed to have killed 11 Pakistani troops in Sibbi
25 One Planet Summit: no climate fix without biodiversity
26 Court points out 5 BLA members in Chinese consulate attack case
27 Mariel Padilla shuns rumor linking husband Robin to Mocha Uson
28 Sesen Bio, Inc. 8-K Jan. 19, 2021 8:00 AM
29 BLA attacks Pak Army post in Bolan, kills 11 personnel
30 ATC indicts five BLA members in Chinese consulate attack case
31 ATC declares 15 BLA members absconders in 2018 Chinese consulate attack
32 As 19th Century Females, Sisters In 'The Doctors Blackwell' Achieve Many Firsts
33 Legislative Changes to FDA’s Orange Book and Purple Book Listing Requirements
34 Biocon shares fall as generic sales disappoint
35 Omar Kakroo to be Continued as President Municipal council Bla as per J&K High court order
36 Alandia and Blå Mediamentor team up to support mental health among seafarers
37 Turner says future vaccine megasites are dependent on supply
38 Narsoplimab Under Review for Stem Cell Transplant-Associated Thrombotic Microangiopathy
39 How Warnock and Ossoff's victories evoked the history of the Black freedom struggle
40 Remembering Eric Jerome Dickey
41 Hanmi Pharmaceutical expects US FDA approval for 2 new drugs
42 An intimate gaze: Ruth Motau on documenting life in black and white
43 Transportation Aggregators Market Dynamics, Target Audience, Forecast by Manufacturers – Beijing Xiaoju Keji Co., Ltd. (Didi Dache), Bla Bla Car, RideScout, Ola, Fehr&Peers, Uber Technologies Inc. (Uber), Vaahika, Aritron, GrabTaxi Pte Ltd Block (Grab Taxi), Gett, Meru, ANI Technologies Pvt. Ltd. (Ola Cabs), Lyft Inc
44 'A Ghastly Future'? Israeli Apartheid, Biden, Starmer, Assange And Mass Extinction
45 Black Lives Matter calls convicted cop killer 'a political prisoner'
46 GDC Bla organises Talk on ‘Establishment of Road Safety Clubs’
47 9 fabulous things to do in Dubai this weekend
48 2 militants killed in Wanigam Bla encounter
49 ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Entry into a Material Definitive Agreement
50 Bla gunfight: One militant killed, operation on
51 DC Bla reviews Covid-19 Vaccination arrangements
52 Karyl Seaman Stewart Obituary
53 GDC Bla, Organises Webinar on 'Structure Based Drug Design, Methods, Protocol
54 Aug 15 2022: PM sets as deadline for U'pur-Bla Rail Link project
55 Shipping majors trying to hit back – too late and too childish
56 Year Ender Report: Udhampur-Bla rail link to be completed by Dec 2022
57 Gig Economy in Insurance Market Outlook 2021-2027, In-depth Analysis of Global Industry Growth, Share, Size and Future Demand by Key Players- Aribnb, Bizzby, Bla Bla Car, Click Worker, City Sprint, Deliveroo, Dinghy, eBay, Fantastic Handyman
58 PFT’s NFL 2020 conference championship game picks
59 Completion of Balstilimab BLA Filing Extended To 1H2021
60 Janssen Files Rolling BLA Submission for on Cilta-Cel in R/R Multiple Myeloma
61 In Dubai, businesses are being creative with 'multi-functional' spaces
62 Push for Public BLA Talks Fail to Sway Council Majority
63 Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer
64 DBV Technologies gains 28% on FDA response regarding Viaskin Peanut application
65 Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLA
66 FDA Will Not Complete Review of BLA for Lisocabtagene Maraleucel By PDUFA Date
67 Jazz (JAZZ) Initiates BLA Submission for Leukemia Candidate
68 Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA
69 Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
70 FDA Accepts BLA for Biogen's Alzheimer's Drug, Grants Priority Review
71 Pandemic travel restrictions force FDA to delay a BLA review — involving a site inspection in Korea
72 ADC Inaugurates 2nd District Taekwondo Championship in Bla
73 FDA Accepts Biogen's BLA for Alzheimer's Candidate Aducanumab
74 CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020
75 FDA Accepts BLA for bluebird and BMS' Multiple Myeloma CAR-T Treatment
76 Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA
77 Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA
78 Janssen Submits BLA for Amivantamab to Treat Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
79 Health Canada Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy
80 Teplizumab BLA for T1D Prevention Submitted
81 Special Meeting on Leesburg BLA Adjourns Without Town Council Quorum
82 U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy
83 J&J (JNJ) Begins Rolling BLA Filing of Multiple Myeloma Drug
84 Gamida Cell Provides Regulatory Update on Biologics License Application for Omidubicel
85 Ascendis Pharma A/S Announces U.S. Food and Drug Administration (FDA) Accepts Biologics License Application (BLA) for TransCon™ hGH for Pediatric Growth Hormone Deficiency (GHD)
86 Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency
87 Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
88 CytoDyn Files Request With FDA for Priority Review of BLA for First Approval
89 TG Therapeutics Initiates BLA for Ublituximab Combo to Treat CLL
90 FDA Review of BLA for Liso-Cel in Relapsed/Refractory Large B-Cell Lymphoma Delayed by COVID-19
91 BMS' CAR T cell therapy BLA accepted for priority review
92 DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years
93 Bluebird: delays push sickle cell therapy BLA back
94 Bristol Myers Squibb Provides Update on Biologics License Application (BLA) for Lisocabtagene Maraleucel (liso-cel)
95 Update on HIV-BLA-PDUFA: FDA requested more information to complete a substantive review. No additional trials required. CytoDyn plans to submit the requested information and will ask for a Type A meeting with the FDA per the agency's suggestion
96 Pogba pledges Man United loyalty after Raiola comments
97 Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the BLA Submission for VicineumTM in December 2020
98 FDA Receives BLA for Lonca in Relapsed/Refractory Diffuse Large B-cell Lymphoma
99 CytoDyn Receives BLA Acknowledgment Letter From the FDA
100 Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma